Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Jeff Bezos participated through Bezos Expeditions in Nautilus Biotechnology’s $76 million Series B, announced in May 2020 and led by Vulcan Capital. Nautilus was co-founded by former Isilon Systems co-founder Sujal Patel and Stanford scientist Parag Mallick to develop tools for measuring proteins and their forms. The round was a company financing—not an acquisition or a personal investment by Bezos outside his investment vehicle.
Who invested in Nautilus Biotechnology’s $76 million round?
Nautilus announced the Series B on May 21, 2020. GeekWire reported that Vulcan Capital led the round, with Bezos Expeditions, Perceptive Advisors and Defy Partners among the new investors. Existing backers including AME Cloud Ventures, Andreessen Horowitz, Bolt and Madrona also participated. Madrona, an existing investor, published its account on May 20, 2020, and likewise named Vulcan, Perceptive, Bezos Expeditions and Defy.vc among the investors.
Bezos’s participation was through Bezos Expeditions, his investment vehicle. The announcement concerned capital raised by Nautilus; it did not report that Bezos bought the company or invested in it personally outside that vehicle. GeekWire’s May 21, 2020 report and Madrona’s May 20, 2020 account describe the financing.
Who founded Nautilus, and what does the company do?
Patel brought company-building experience as a co-founder of Isilon Systems. Mallick, a Stanford scientist, worked at the intersection of proteomics, systems biology and computation. Their complementary backgrounds informed Nautilus’s plan to combine hardware, software, sample handling and computational analysis in a research platform.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →#1 Best Overall
Proteomics is the study of proteins in biological samples. Proteoforms are the different molecular forms a protein can take, including forms produced by modifications or processing. Measuring these forms can help researchers investigate biology that a simple count of protein types may not capture. Nautilus has described its goal as making such measurements useful in scientific research and drug development; that ambition is not evidence that its technology has established clinical benefit or a validated diagnostic test.
In a GeekWire interview published May 21, 2020, Mallick described the opportunity this way: “If you can fundamentally change the way that people do biological research, that is an opportunity that doesn’t come along, ever,” The statement reflects his view of the company’s potential at the time, not a demonstrated outcome. GeekWire’s 2020 coverage also outlined the founders’ backgrounds and the platform concept.
What is Nautilus offering now, and what remains planned?
Nautilus’s named platform is Voyager. Its July 28, 2026 company update described Voyager as not yet commercially available and set out a roadmap of future milestones. These are company forecasts, not completed launches; Nautilus said development timelines could change.
| Offering or milestone | Status and timing in the company’s July 28, 2026 update |
|---|---|
| Iterative Mapping Early Access | A services-based program began in Q1 2026, initially using the Tau Proteoforms Assay. The company said the assay continued through Early Access. |
| Tau consumable assay kits | General availability was expected in mid-2027; this was a forecast. |
| AKT1 oncology assay | Early Access was expected to begin in late 2026, with kits expected in mid-2027. Both dates were forecasts. |
| Voyager instrument | Pre-orders were expected in early 2027 and instrument shipments in mid-2027. Neither milestone had occurred as of the July 2026 update. |
| Broadscale consumable assays | No commercial timeline was provided. Nautilus said changes to its assay configuration did not meet target specifications for general availability in 2027. |
The distinctions matter: the Early Access program was a service offering, while instrument orders, shipments and general availability of kits were future milestones. The company’s July 2026 update is available in its Q2 2026 report filed with the SEC.
What do Nautilus’s recent financial results show?
In its Q2 2026 report, Nautilus said revenue was $0.2 million for the quarter, primarily from grant activity and initial Early Access service sales. The same company report listed $15.9 million in operating expenses and a $14.5 million net loss for Q2 2026, and $129.2 million in cash, cash equivalents and investments as of June 30, 2026. These figures describe the company’s position more than six years after the Series B; they should not be read as details of how the 2020 round’s proceeds were used.
In the same July 28, 2026 release, CEO Sujal Patel said: “The second quarter reinforced our ever-increasing conviction that proteoforms deliver critical biological resolution that Nautilus is uniquely positioned to deliver,” This is the company’s positioning, not an independent assessment of product performance. The release does not establish clinical performance or diagnostic validation figures.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How the 2020 financing fits into the company’s timeline
Nautilus was founded in 2016 and went public in 2021 through a SPAC, according to GeekWire’s 2025 company coverage. That article also reported a workforce reduction and an anticipated 2026 product release. The company’s later July 2026 roadmap is the more current source for product timing: it shifted Voyager pre-orders and shipments to 2027 and described the platform as not yet commercially available.
The Series B is therefore best understood as an early financing milestone in a still-developing research-technology company. Nautilus’s recent report shows that it had begun limited Early Access services, while its instrument and several assay-kit milestones remained in the future. GeekWire’s 2025 account provides intervening company history; product dates above reflect the company’s July 2026 update.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
